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Aims: To assess the benefits of intensive statin therapy on reducing cardiovascular (CV) events in patients with type 2 diabetes complicated with hyperlipidaemia and retinopathy in a primary prevention setting in Japan. In the intension-to-treat population, intensive therapy [targeting LDL cholesterol <1.81 mmol/L (<70 mg/dL)] was no more effective than standard therapy [LDL cholesterol ≥2.59 to <3.10 mmol/L (≥100 to <120 mg/dL)]; however, after 3 years, the intergroup difference in LDL cholesterol was only 0.72 mmol/L (27.7 mg/dL), and targeted levels were achieved in <50% of patients. We hypothesized that the intergroup difference in CV events would have been statistically significant if more patients had been successfully treated to target.
Materials and Methods:
This exploratory post hoc analysis focused on intergroup data from patients who achieved their target LDL cholesterol levels. The primary endpoint was the composite incidence of CV events. A Cox proportional hazards model was used to estimate hazard ratios (HRs) for incidence of the primary endpoint in patients who achieved target LDL cholesterol levels in each group.
Results: Data were analysed from 1909 patients (intensive: 703; standard: 1206) who achieved target LDL cholesterol levels. LDL cholesterol at 36 months was 1.54 AE 0.30 mmol/L (59.7 AE 11.6 mg/dL) in the intensive group and 2.77 AE 0.46 mmol/L (107.1 AE 17.8 mg/dL) in the standard group (P < 0.05). After adjusting for baseline prognostic factors, the composite incidence of CV events or deaths associated with CV events was significantly lower in the intensive than the standard group (HR 0.48; 95% confidence interval 0.28-0.82; P = 0.007).
Conclusions:
This post hoc analysis suggests that achieving LDL cholesterol target levels <1.81 mmol/L may more effectively reduce CV events than achieving target levels ≥2.59 to <3.10 mmol/L in patients with hypercholesterolaemia and diabetic retinopathy. Each of these conditions is a known risk factor for cardiovascular disease (CVD), and the risk of a cardiovascular (CV) event is even higher in patients with both conditions. [1] [2] [3] Among patients with diabetes, the CV risk is known to be further increased in patients whose diabetes is complicated by retinopathy; such patients are recognized to be at very high risk for CVD. 4, 5 The EMPATHY study is the first to assess the benefits of intensive statin therapy in patients with type 2 diabetes with hyperlipidaemia and diabetic retinopathy in a primary prevention setting, and also the first large-scale clinical study to evaluate the effectiveness of the treat-to-target approach. The study compared the benefits of intensive and standard statin therapy for reducing a composite of CV events or deaths from CV events (the primary endpoint 6 These findings appeared to contradict earlier findings that showed benefits of lower LDL cholesterol in patients with diabetes. [7] [8] [9] Notably, however, the LDL cholesterol target in the EMPATHY study was achieved by fewer than half of the patients in either group. In addition, a large percentage of patients on standard therapy in the original study (targeting ≥2.59 to <3.10 mmol/L) actually achieved LDL cholesterol levels below the target range ( Figure 1 ). These factors may have contributed to masking the efficacy of the intensive therapy.
To further investigate the efficacy of intensive therapy, we conducted additional exploratory analyses of between-group comparisons. Although previous large-scale clinical studies of statins have included exploratory (post hoc) analyses stratified by lipid levels achieved, in all cases, these sub-analyses were for dose comparison studies. More importantly, none of the studies assessed whether the patients achieved prespecified goals for LDL cholesterol levels. 10, 11 We limited our sub-analyses to those patients whose LDL cholesterol levels were within the targeted range, in order to better assess the effects of the treat-to-target approach in these patient populations. Our hypothesis was that intensive therapy in patients who achieved their target (LDL cholesterol <1.81 mmol/L) would be superior to standard therapy (LDL cholesterol target ≥2.59 to <3.10 mmol/L) in reducing the incidence of composite CV events.
| MATERIALS AND METHODS

| Study design
The EMPATHY study was conducted to determine whether intensive lipid-lowering therapy is superior to standard therapy in reducing the incidence of CV events or death from CV events in patients with type 2 diabetes complicated by hyperlipidaemia and diabetic retinopathy and without a history of CVD. 6, 12 The study used a multicentre, pro- 
| Patients
This sub-analysis was performed on data collected from patients in the EMPATHY study who achieved mean LDL cholesterol levels of <1.81 mmol/L in the intensive therapy group in the original study (the intensive group) and ≥2.59 to <3.10 mmol/L in the standard therapy group in the original study (the standard group). The mean LDL cholesterol for each patient was defined as the mean value of measurements obtained at scheduled visits, starting 6 months after randomization to the intensive therapy group or the standard therapy group in the original study, and continuing to the final visit for those who developed no events or to the nearest day before onset for those who developed any events.
| Procedures
Analysis included all patients who had at least one scheduled visit during the period starting 6 months after randomization. For reference, in comparison to these mean values, additional analysis was performed on data collected from patients who showed the target LDL cholesterol level at their last visit. The last visit was defined to be the nearest day before onset of an event for patients who developed any events, or the date of the final visit for patients who did not develop any events during the scheduled visits, starting 6 months after randomization to a treatment group.
| Outcomes
In the EMPATHY study, the primary outcome was the composite incidence of CV events, including cardiac, cerebral, renal and vascular events, or death associated with CV events. The secondary outcomes included death from any cause; individual incidence of the events defined as CV events for the primary endpoint; incidence of stroke; change in laboratory variables related to chronic kidney disease; and safety. Primary and secondary endpoints were adjudicated by an event evaluation committee whose members were unaware of the treatment allocation. In this sub-analysis, we analysed only the primary outcome and safety because of the small number of CV events.
| Statistical analysis
A Cox proportional hazards model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the incidence of the primary endpoint in patients who achieved target LDL cholesterol levels in the intensive and standard groups. Because this additional analysis was performed in a sub-group of patients, a Cox proportional hazards model was applied, with study group and baseline influencing factors as explanatory variables, to adjust for these factors. 3 | RESULTS
| Study participants
Of the 5144 patients randomized to the intensive and standard therapy groups in the EMPATHY study, a total of 1909 were included in this sub-analysis (703 in the intensive group and 1206 in the standard group). A total of 70 patients (25 in the intensive group and 45 in the standard group) had only one scheduled visit at least 6 months after randomization.
| Baseline characteristics
Some of the demographic characteristics of the patients in both groups at baseline were similar (age, family history of coronary artery disease and/or cerebrovascular disease, presence of neuropathy and/or nephropathy, severity of retinopathy, HbA1c levels and eGFR), while other characteristics differed between the groups ( The demographic characteristics of the patients who were at their target LDL cholesterol level at the last visit were similar to those who were at their mean target LDL cholesterol level, with the exception of nephropathy (Table S1 , Appendix S1).
The proportion of patients using atorvastatin, rosuvastatin or pitavastatin was about the same in the two groups at baseline (48.2% in the intensive group and 53.1% in the standard group), and the proportion using pravastatin, fluvastatin or simvastatin was 51.2% and 46.7%, respectively. At the end of the study, the proportion of atorvastatin, rosuvastatin or pitavastatin users remained nearly unchanged in the standard group (50.9%), but had risen to 98.2% in the intensive group. Dose levels at baseline were similar in the intensive and standard groups for all statins.
In the intensive group, the dose increased for all statin types over the course of the study. The doses did not change for the standard group (Table S2 , Appendix S1). It should be noted that the statin dose for "intensive" therapy in Japan is lower than in the United States and Europe.
| Laboratory values
The changes in levels of LDL cholesterol, total cholesterol, HDL cholesterol and triglycerides in the sub-analysis are shown in Figure 2 . In LDL cholesterol in both groups. Triglyceride levels were slightly higher in the intensive group at baseline, but that gap diminished somewhat after the start of the study. HDL cholesterol remained substantially unchanged throughout the study in both groups.
No changes were noted for either group during the study in blood pressure, HbA1c, creatinine or creatine kinase; however, in the intensive group, high-sensitivity C-reactive protein (hsCRP) levels were significantly reduced at all time points except 60 months, and there was a significant difference between the groups in hsCRP (Table S3 , Appendix S1).
| Efficacy endpoints
Since stepwise variable selection showed that eight factors were statistically related to the primary outcome among the 15 potential prognostic factors, the analysis was adjusted for these variables: gender; smoking status (current smoker, past smoker, non-smoker); presence or absence of diabetic nephropathy, neuropathy, or hypertension; funduscopic findings at enrolment; HbA1c at informed consent; and eGFR at enrolment (<60,
). Baseline LDL cholesterol was not found to be a prognostic factor. We adjusted for these eight prognostic factors to estimate HRs and 95% CIs for the incidence of CV events (the primary endpoint of the EMPATHY study).
In this sub-analysis, a significantly smaller proportion of patients in the intensive group (18/703 patients) experienced CV events or death associated with CV events than in the standard group (56/1206 patients; HR 0.48, 95% CI 0.28-0.82; P = 0.007 [ Figure 3 and Table S4 , Appendix S1]). This difference between the groups started at~12 months after randomization. These findings remained unchanged even if baseline LDL cholesterol was added as a ninth prognostic factor (data not shown).
In the above sub-analysis, we used mean LDL cholesterol values to determine whether each patient achieved the target range. We then repeated our analysis using LDL cholesterol values at the last visit. In this analysis we also noted a significant difference in the primary endpoint between the intensive group and the standard group (HR 0.43, 95% CI 0.27-0.68; P < 0.001 [ Figure 4 ]).
| Safety
The safety endpoints examined in this analysis were adverse events (AEs), serious AEs, adverse drug reactions (ADRs) and serious ADRs.
There was no significant difference in the incidence rates for each of these endpoints between the two groups. The major AEs were hepatobiliary disorders, renal and urinary disorders, rhabdomyolysis, myopathy and cancer (Table S5 , Appendix S1). Overall, the occurrence of these events in the two groups was similar except for renal and urinary disorders, which were more common in the standard group (9.2%) than in the intensive group (5.7%).
| DISCUSSION
The EMPATHY study assessed the benefits of intensive statin monotherapy for lipid management in patients with type 2 diabetes complicated by hypercholesterolaemia and diabetic retinopathy in a primary prevention setting. The study also evaluated the appropriate- Table S6 ,
Appendix S1]). Safety events occurred at approximately the same rate in the two groups.
We used mean values for LDL cholesterol in patients who achieved their target levels because we thought it was important to ensure that patients were exposed to a specific concentration of LDL cholesterol for a certain period of time. Our results, although exploratory, suggest that achieving a target of <1.81 mmol/L LDL cholesterol lowers the risk of CV events significantly more than achieving a target of 2.59 to 3.10 mmol/L. For reference, we have also provided a summary of our findings for the proportion of patients who achieved their target LDL cholesterol level at the last visit. Results were similar to those based on mean values.
In the main results paper, we performed post hoc analysis, which involved classifying patient data into four subcategories (mean LDL cholesterol <1.81, 1.81 to <2.59, 2.59 to <3.10, and ≥3.10 mmol/L during the study). That analysis tended to show event prevention at lower LDL cholesterol values in both the intensive and standard therapy groups in the original study 6 ; the results of the present subanalysis are consistent with those findings. This fact supports the reliability of our sub-analysis. Although exploratory, we believe that these findings could meaningfully impact lipid management in clinical practice for the primary prevention of CV events in patients with type 2 diabetes with hyperlipidaemia and diabetic retinopathy.
Previous large-scale clinical studies of statins have also used LDL cholesterol levels as a basis for post hoc sub-analyses, [8] [9] [10] [11] and usefulness was demonstrated in groups achieving lower target levels; however, all of these sub-analyses were in dose comparison studies, and none assessed whether patients had achieved their target LDL cholesterol levels. To the best of our knowledge, no other analyses have been reported that show the effect of specified target LDL cholesterol levels using statin monotherapy on the occurrence of CV events or CV-related deaths. Although this was an exploratory analysis, our data are valuable when assessing the importance of the treat-to-target approach in lipid management.
In the ITT analysis for the EMPATHY study, the difference in LDL cholesterol between the two groups was 0.72 mmol/L, and the HR for the primary endpoint was 0.84 (95% CI 0.67-1.07; P = 0.15). 6 In this sub-analysis, LDL cholesterol at 36 months was 1 occurrence between the two groups. These sub-analysis findings indicate that we were unable to obtain significant results from the main analysis because of failure to achieve target LDL cholesterol levels.
No major differences were noted between groups in the incidence of AEs or ADRs. It thus appears unlikely that specific safety concerns will occur when intensive statin monotherapy is used to reduce LDL cholesterol below 1.81 mmol/L. We found no marked increase in cerebral haemorrhage in the intensive group (two patients in the intensive group, one patient in the standard group), nor any increase in HbA1c associated with statin use in this study.
These study findings are limited because they are derived from an exploratory analysis which included only those patients whose LDL (Table S4 , Appendix S1). In addition, although we detected and adjusted for eight prognostic factors, there FIGURE 4 Cumulative event curve for the primary endpoint in the intensive and standard groups (patients achieving LDL cholesterol target at the last visit). Hazard ratio (HR), 95% confidence interval (CI) and P value are estimated using a Cox proportional hazards model with gender (male, female), smoking status, presence or absence of diabetic nephropathy, presence or absence of diabetic neuropathy, presence or absence of hypertension, funduscopic findings, and baseline glycated haemoglobin (<8.4, ≥8.4%) and estimated glomerular filtration rate (< 60, ≥60 mL/min/1.73 m 2 ) as covariates may be additional unmeasured factors or confounding factors that should be considered.
In conclusion, the results from this exploratory post hoc analysis suggest that achievement of LDL cholesterol levels below 1.81 mmol/L is associated with more effective reduction of CV events than levels of 2.59 to 3.10 mmol/L in patients with type 2 diabetes with retinopathy and hyperlipidaemia who are at high coronary risk. 4, 5 
